期刊文献+

稳定沉默Rictor表达的前列腺癌CWR22RV1的构建 被引量:1

Construct a prostate cancer cell line CWR 22RV1 with Rictor-shRNA
下载PDF
导出
摘要 目的应用RNA沉默技术下调前列腺癌CWR22RV1细胞株的Rictor基因表达,并筛选具有稳定转染Rictor-shRNA的细胞株,为进一步研究Rictor在前列腺癌中的作用打下基础。方法针对Rictor基因设计合成siRNA序列;鉴定、测序并转染293T细胞观察基因表达情况;构建Rictor-shRNA慢病毒载体;进行Rictor-shRNA慢病毒包装及滴度测定;筛选稳定表达Rictor-shRNA的前列腺癌CWR22RV1细胞株;Western blot检测稳定转染前列腺癌CWR22RV1细胞株Rictor的表达水平。结果 Rictor-shRNA慢病毒成功包装后转染前列腺癌CWR22RV1细胞,进行嘌呤霉素筛选,获得沉默Rictor基因的前列腺癌CWR22RV1细胞株,Western blot检测显示该细胞株Rictor水平明显降低(P<0.01)。结论成功构建了稳定沉默Rictor表达的前列腺癌CWR22RV1细胞株,为后续的实验了打下坚实的基础。 Objective To establish a prostate cancer cell line CWR22RV1 with Rictor stably silenced by using RNAi, and provide a basis to further study the role of Rictor in prostate cancer. Methods We have designed and synthesized the subsequence of siRNA aimed to Rictor,and identify, sequence the subsequence of siRNA , and transfect 293T cells to observe the expression of Rictor. Construct a lentiviral vector carrying the Rictor-shRNA. We have packaged a lentiviral vector carry- ing the Rictor-sbRNA and viral titer is determined. Screening a prostate cancer cell line CWR22RV1 with Rictor stably silenced by using RNAi. The expression of Rictor in prostate cancer cell line CWR22RV1 with Rictor shRNA was examined by Western blot. Results We had successfully constructed a lentiviral vector carrying the Rictor-shRNA, and transfected into prostate cancer cell line CWR22RV1, screening prostate cancer cell line CWR22RV1 with Rictor-shRNA with puromycin, and obtained prostate cancer cell line CWR22RV1 with Rietor was stably silenced, the expression of Rictor in prostate cancer cell line CWR22RV1 with Rictor-shRNA was significant deceased (P〈0.01). Conclusions We had successfully established a prostate caneer cell line CWR22RV1 with Rictor was stably silenced, which provided a basis to further study the prostate cancer.
出处 《现代泌尿生殖肿瘤杂志》 2012年第4期219-222,共4页 Journal of Contemporary Urologic and Reproductive Oncology
基金 教育部博士点基金(20113420110003) 安徽省自然科学基金(1208085MH138)
关键词 前列腺肿瘤 RICTOR 慢病毒属 CWR22RV1 Prostatic neoplasms Rictor Lentiviral CWR22RV1
  • 相关文献

参考文献13

  • 1Guertin DA, Sabatini DM. Defining the role of mTOR in cancer[J]. Cancer Ce11,2007,12(1) :9-22.
  • 2Sabatini DM. mTOR and cancer: insights into a complex re- lationship[J]. Nat Rev Cancer,2006,6(9):729 -734.
  • 3Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feed backs and cross-talks[J]. Oncogene,2008,27(41) :5527-5541.
  • 4Sarbassov DD, Guertin DA, All SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex[J]. Science,2005,307(5712) :1098- 1101.
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J]. CA CancerJ Clin,2012,62(1):10 -29.
  • 6Miki J, Furusato B, Li H, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortal ized primary nonmalignant and malignant tumovderived hu man prostate epithelial cell lines and in prostate cancer speci- mens[J]. Cancer Res,2007,67(7) :3153-3161.
  • 7Cho D, Signoretti S, Regan M, et al. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer[J]. Clin Cancer Res, 2007,13 (2 Pt 2) : 758s-763s.
  • 8Zeng Z, Sarbassov dos D, Samudio IJ, et al. Rapamycin de- rivatives reduce mTORC2 signaling and inhibit AKT activa- tion inAML[J]. Blood,2007,109(8):3509 -3512.
  • 9Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy[J]. Onco- gene, 2010,29 (26) : 3733-3744.
  • 10Attard G, Cooper CS, de Bono JS. Steroid hormone recep torsin prostate cancer: a hard habit to break[J]. Cancer Ce11,2009,16(6) :458-462.

同被引文献11

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部